المؤلفون: Junho Lee, Sana Mansoor, Jeongjun Lee, Hunsuk Chung, Young-Sam Kwon, Khawaja Muhammad Imran Bashir, Jae-Suk Choi, Sae-Kwang Ku

المصدر: Applied Sciences, Vol 15, Iss 1, p 99 (2024)

مصطلحات موضوعية: antioxidant activity, anti-inflammatory, Atractylodes japonica, herbal medicine, mucolytic expectorant, respiratory protection, Technology, Engineering (General). Civil engineering (General), TA1-2040, Biology (General), QH301-705.5, Physics, QC1-999, Chemistry, QD1-999

وصف الملف: electronic resource

Relation: https://www.mdpi.com/2076-3417/15/1/99; https://doaj.org/toc/2076-3417

URL الوصول: https://doaj.org/article/0e64896745634e31818a6a2df19f66d7

المؤلفون: Nilanjan Pahari, Arup Chatterjee, Chandan Dandapat

المصدر: Hybrid Advances, Vol 6, Iss , Pp 100266- (2024)

مصطلحات موضوعية: Antioxidants, Mucolytic, BHELE, OECD, Mortality, Technology

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2773207X24001271; https://doaj.org/toc/2773-207X

URL الوصول: https://doaj.org/article/b37871e53c524e519f0278168916b3bb

المؤلفون: Sergey L. Babak, Marina V. Gorbunova, Andrey G. Malyavin

المصدر: Consilium Medicum, Vol 25, Iss 9, Pp 623-628 (2023)

مصطلحات موضوعية: ambroxol, mucociliary clearance, tracheobronchial secretion, secretolytic activity, mucokinetic activity, mucolytic therapy, nonproductive cough, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://consilium.orscience.ru/2075-1753/article/viewFile/609545/138194; https://doaj.org/toc/2075-1753; https://doaj.org/toc/2542-2170

URL الوصول: https://doaj.org/article/f37440f4beb54f199fd3e5ff679a9bc9

المؤلفون: Gopinathan Gangadharan Nambiar, Sussette Gonzalez Szachowicz, Christian F. Zirbes, Jared J. Hill, Linda S. Powers, David K. Meyerholz, Ian M. Thornell, David A. Stoltz, Anthony J. Fischer

المصدر: Frontiers in Pediatrics, Vol 12 (2024)

مصطلحات موضوعية: meconium, cystic fibrosis, meconium ileus, pancreatic enzymes, mucus, mucolytic, Pediatrics, RJ1-570

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fped.2024.1387171/full; https://doaj.org/toc/2296-2360

URL الوصول: https://doaj.org/article/1b4483c0066844d2a9383238af8cf27f

المؤلفون: Vitri, Desy Aryanti Pardilla, Aini, Siti Rahmatul, Saputri, Legis Ocktaviana

المساهمون: The authors claim that the research was self-funded.

المصدر: Biology, Medicine, & Natural Product Chemistry; Vol 13, No 2 (2024); 541-547 ; 2540-9328 ; 2089-6514

مصطلحات موضوعية: Medicine Journal, Biology Journal, Journal Natural product, Cardamom Fruit, Decoction, Duck Egg Albumens, In Vitro, Mucolytic

وصف الملف: application/pdf

Relation: https://www.sciencebiology.org/index.php/BIOMEDICH/article/view/604/321; https://www.sciencebiology.org/index.php/BIOMEDICH/article/view/604

الاتاحة: https://www.sciencebiology.org/index.php/BIOMEDICH/article/view/604
https://doi.org/10.14421/biomedich.2024.132.541-547

المؤلفون: Muralinath E., Pooja Devi., Nikhil Ch.Nath, Champak B., Kalyan C., Archana Jain, Guruprasad M.

المصدر: Journal of Advanced Research and Reviews in Medical & Medicine, 1(1), 1 - 3, (2024-01-18)

مصطلحات موضوعية: Atelectasis, airway obstruction. Compression of lung tissue, broncho dilator, anti-cholinergic, beta _ agonists, broncho constriction, mucolytic agents namely acetyl cysteine, mucus viscosity surfactant replacement therapy (SRT), neonates, exogenous surfactant, corticosteroids, positive airway pressure (PAP), continuous positive airway pressure (c PAP), Bi_ level positive airway pressure (B PAP) and oxygen therapy

Relation: https://zenodo.org/communities/pharmapub; https://doi.org/10.5281/zenodo.10526220; https://doi.org/10.5281/zenodo.10526221; oai:zenodo.org:10526221

الاتاحة: https://doi.org/10.5281/zenodo.10526221

المؤلفون: Betancourth Sanmartín, Kevin, Méndez Mendoza, Karla Nicole, Domínguez Villizhanay , Juan Diego, León Martínez , Fernando Mauricio

المصدر: Mediciencias UTA; Vol. 8 No. 3 (2024): July - University Magazine with projection; 111 - 122 ; Mediciencias UTA; Vol. 8 Núm. 3 (2024): Julio - Revista Universitaria con proyección; 111 - 122 ; Mediciencias UTA; Vol. 8 N.º 3 (2024): Julio - Revista Universitaria con proyección; 111 - 122 ; 2550-6765 ; 2602-814X ; 10.31243/mdc.uta.v8i3

مصطلحات موضوعية: Tratamiento, Acetilcisteína, Enfermedades Neurodegenerativas, Mucolítitco, Treatment, Acetylcysteine, Neurodegeneratives Diseases, Mucolytic

وصف الملف: application/pdf

Relation: https://revistas.uta.edu.ec/erevista/index.php/medi/article/view/2337/3001; https://revistas.uta.edu.ec/erevista/index.php/medi/article/view/2337

الاتاحة: https://revistas.uta.edu.ec/erevista/index.php/medi/article/view/2337
https://doi.org/10.31243/mdc.uta.v8i3.2337.2024

المؤلفون: S. N. Avdeev, E. I. Kondratyeva, R. S. Kozlov, L. S. Namazova-Baranova, E. Kh. Anaev, Yu. L. Mizernitskiy, A. V. Lyamin, S. K. Zyryanov, Т. E. Gembitskaya, E. A. Tarabrin, L. R. Selimzyanova, S. I. Kutsev, С. Н. Авдеев, Е. И. Кондратьева, Р. С. Козлов, Л. С. Намазова-Баранова, Э. Х. Анаев, Ю. Л. Мизерницкий, А. В. Лямин, С. К. Зырянов, Т. Е. Гембицкая, Е. А. Тарабрин, Л. Р. Селимзянова, С. И. Куцев

المساهمون: The article was prepared with the financial support of Solopharm, Статья подготовлена при финансовой поддержке компании Solopharm

المصدر: PULMONOLOGIYA; Том 34, № 2 (2024); 158-174 ; Пульмонология; Том 34, № 2 (2024); 158-174 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: муколитическая и антибактериальная терапия, computed tomography, microbiology, mucolytic and antibacterial therapy, компьютерная томография, микробиология

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/4474/3637; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4474/2501; Laennec R.T.H. A treatise on the disease of the chest: with plates. New York: Academy Medicine; 1962. Available at: https://archive.org/details/treatiseondiseas0000laen/page/n1/mode/2up; Cole P.J. Inflammation: a two-edged sword – the model of bronchiectasis. Eur .J. Respir. Dis. Suppl. 1986; 147: 6–15.; Pembridge T., Chalmers J.D. Precision medicine in bronchiectasis. Breathe (Sheff). 2021; 17 (4): 210119. DOI:10.1183/20734735.0119-2021.; Рачинский С.В., Таточенко В.К., ред. Болезни органов дыхания у детей. М.: Медицина; 1988.; Розинова Н.Н., Мизерницкий Ю.Л., ред. Хронические заболевания легких у детей. М.: Практика; 2011.; Таточенко В.К., ред. Болезни органов дыхания у детей. М.: Педиатръ, 2012.; Eber E., Midulla F., eds. ERS handbook paediatric respiratory medicine. 2nd Edn. Sheffield: ERS; 2021. DOI:10.1183/9781849841313.eph01.; Lowe D.M., Hurst J.R. Primary immunodeficiency. In: Chalmers J.D., Polverino E., Aliberti S., eds. Bronchiectasis. Sheffield: ERS; 2018: 153–166. DOI:10.1183/2312508X.10015917.; Polverino E., Goeminne P.C., McDonnell M.J. et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur. Respir. J. 2017; 50 (3): 1700629. DOI:10.1183/13993003.00629-2017.; Chang A.B., Fortescue R., Grimwood K. et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur. Respir. J. 2021; 58 (2): 2002990. DOI:10.1183/13993003.02990-2020.; Weycker D., Edelsberg J., Oster G., Tino G. Prevalence and economic burden of bronchiectasis. Clin. Pulm. Med. 2005; 12 (4): 205–209. DOI:10.1097/01.cpm.0000171422.98696.ed.; Feng J., Sun L., Sun X. et al. Increasing prevalence and burden of bronchiectasis in urban Chinese adults, 2013-2017: a nationwide population-based cohort study. Respir. Res. 2022; 23 (1): 111. DOI:10.1186/s12931-022-02023-8.; Bilton D., Jones A.L. Bronchiectasis: epidemiology and causes. In: Floto R.A., Haworth C.S., eds. Bronchiectasis (out of print). Sheffield: ERS; 2011. Vol. 52: 1–10. DOI:10.1183/1025448x.erm5210.; Flume P.A., Chalmers J.D., Olivier K.N. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018; 392 (10150): 880–890. DOI:10.1016/S0140-6736(18)31767-7.; Contarini M., Finch S., Chalmers J.D. Bronchiectasis: a case-based approach to investigation and management. Eur. Respir. Rev. 2018; 27 (149): 180016. DOI:10.1183/16000617.0016-2018.; Altenburg J., Wortel K., van der Werf T.S., Boersma W.G. Non-cystic fibrosis bronchiectasis: clinical presentation, diagnosis and treatment, illustrated by data from a Dutch Teaching Hospital. Neth. J. Med. 2015; 73 (4): 147–154. Available at: https://www.njmonline.nl/article.php?a=1561&d=1036&i=182; Smith M.P. Diagnosis and management of bronchiectasis. CMAJ. 2017; 189 (24): E828–835. DOI:10.1503/cmaj.160830.; Ullmann N., Porcaro F., Petreschi F. et al. Noncystic fibrosis bronchiectasis in children and adolescents: Follow-up over a decade. Pediatr. Pulmonol. 2021; 56 (9): 3026–3034. DOI:10.1002/ppul.25553.; Pasteur M.C., Bilton D., Hill A.T.; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010; 65 (7): 577. DOI:10.1136/thx.2010.142778.; Красовский С.А., Старинова А.Ю., Воронкова Е.Л. и др., ред. Регистр больных муковисцидозом в Российской Федерации. 2021 год. СПб: Благотворительный фонд «Острова»; 2023. Доступно на: https://mukoviscidoz.org/doc/registr/registr_systicfibrosis_brochure_19_10.pdf; King P.T., Holdsworth S.R., Freezer N.J. et al. Microbiologic follow-up study in adult bronchiectasis. Respir. Med. 2007; 101 (8): 1633–1638. DOI:10.1016/j.rmed.2007.03.009.; Cummings S., Nelson A., Purcell P. et al. A comparative study of polymicrobial diversity in CF and non-CF bronchiectasis. Thorax. 2010; 65 (4): A13–A14. DOI:10.1136/thx.2010.150912.23.; Foweraker J.E., Wat D. Microbiology of non-CF bronchiectasis. In: Floto R.A., Haworth C.S., eds. Bronchiectasis (out of print). Sheffield: ERS; 2011. Vol. 52: 68–96. DOI:10.1183/1025448x.10003610.; Finch S., McDonnell M.J., Abo-Leyah H. et al. A Comprehensive analysis of the impact of pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann. Am. Thorac. Soc. 2015; 12 (11): 1602–1611. DOI:10.1513/AnnalsATS.201506-333OC.; Pasteur M.C., Helliwell S.M., Houghton S.J. et al. An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 2000; 162 (4, Pt 1): 1277–1284. DOI:10.1164/ajrccm.162.4.9906120.; Reid L.M. Reduction in bronchial subdivision in bronchiectasis. Thorax. 1950; 5 (3): 233–247. DOI:10.1136/thx.5.3.233.; Angrill J., Agusti C., De Celis R. et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am. J. Respir. Crit. Care Med. 2001; 164 (9): 1628–1632. DOI:10.1164/ajrccm.164.9.2105083.; Chang A.B., Masel J.P., Boyce N.C. et al. Non-CF bronchiectasis: clinical and HRCT evaluation. Pediatr. Pulmonol. 2003; 35 (6): 477–483. DOI:10.1002/ppul.10289.; Remy Jardin M., Amara A., Campistron P. et al. Diagnosis of bronchiectasis with multislice spiral CT: accuracy of 3-mm-thick structured sections. Eur. Radiol. 2003; 13 (5): 1165–1171. DOI:10.1007/s00330-003-1821-z.; Naidich D.P., McCauley D.I., Khouri N.F. et al. Computed tomography of bronchiectasis. J. Comput. Assist. Tomogr. 1982; 6 (3): 437–444. DOI:10.1097/00004728-198206000-00001.; Hill T.A., Sullivan L.A., Chalmers D.J. et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019; 74 (Suppl. 1): 1–69. DOI:10.1136/thoraxjnl-2018-212463.; UpToDate. Barker A.F. Clinical manifestations and diagnosis of bronchiectasis in adults. 2023. Available at: https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-bronchiectasis-in-adults/print [Accessed: December 05, 2023].; Martinez-Garcia M.Á., Oscullo G., Garcia-Ortega A. Towards a new definition of non-cystic fibrosis bronchiectasis. J. Bras. Pneumol. 2022; 48 (1): e20220023. DOI:10.36416/1806-3756/e20220023.; Hill A.T., Haworth C.S., Aliberti S. et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur. Respir. J. 2017; 49 (6): 1700051. DOI:10.1183/13993003.00051-2017.; Castellani C., Simmonds N.J. Identifying undiagnosed cystic fibrosis in adults with bronchiectasis. In: Chalmers J.D., Polverino E., Aliberti S., eds. Bronchiectasis. Sheffield: ERS; 2018: 29–44. DOI:10.1183/2312508X.10015317.; Patel I.S., Viahos I., Wilkinson T.M. et al. Bronchiectasis, exacerbation indices and inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170 (4): 400–407. DOI:10.1164/rccm.200305-648oc.; Ellis D.A., Thornley P.E., Wightman A.J. et al. Present outlook in bronchiectasis: clinical and social study and review of factors influencing prognosis. Thorax. 1981; 36 (9): 659–664. DOI:10.1136/thx.36.9.659.; Martínez-García M.Á., de Gracia J., Vendrell Relat M. et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur. Respir. J. 2014; 43 (5): 1357–1367. DOI:10.1183/09031936.00026313.; Lee A.L., Burge A.T., Holland A.E. Airway clearance techniques for bronchiectasis. Cochrane Database Syst. Rev. 2015; 2015 (11): CD008351. DOI:10.1002/14651858.cd008351.pub3.; Мизерницкий Ю.Л., Новак А.А., Шудуева А.Р. Опыт ингаляционного применения гипертонического раствора в пульмонологии детского возраста. Медицинский Совет. 2022; 16 (12): 36–39. DOI:10.21518/2079-701X-2022-16-12-36-39.; Nicolson C.H., Stirling R.G., Borg B.M. et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir. Med. 2012; 106 (5): 661–667. DOI:10.1016/j.rmed.2011.12.021.; Gao Y.H., Guan W.J., Xu G. et al. Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. PLoS One. 2014; 9 (3): e90047. DOI:10.1371/journal.pone.0090047.; White L., Mirrani G., Grover M. et al. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir. Med. 2012; 106 (3): 356–360. DOI:10.1016/j.rmed.2011.11.018.; Polverino E., Perez-Miranda J. Antibiotic management and resistance. In: Chalmers J.D., Polverino E., Aliberti S., eds. Bronchiectasis. Sheffield: ERS; 2018. Vol. 81: 312–330. DOI:10.1183/2312508x.erm8118.; UpToDate. Goyal V., Chang A.B. Bronchiectasis in children without cystic fibrosis: Management. Available at: https://www.uptodate.com/contents/management-of-bronchiectasis-in-children-without-cystic-fibrosis [Accessed: September 21, 2021].; Shapiro A.J., Zariwala M.A., Ferkol T. et al. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatr. Pulmonol. 2016; 51 (2): 115–132. DOI:10.1002/ppul.23304.; Brodt A.M., Stovold E., Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur. Respir. J. 2014; 44 (2): 382–393. DOI:10.1183/09031936.00018414.; Choi S.H., Kim E.Y., Kim Y.J. Systemic use of fluoroquinolone in children. Korean J. Pediatr. 2013; 56 (5): 196–201. DOI:10.3345/kjp.2013.56.5.196.; Gardner R.A., Davis S.D., M. Rosenfeld M. et al. Therapies used for primary ciliary dyskinesia in North American children. Am. J. Respir. Crit. Care Med. 2021; 203: A3380. DOI:10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A3380.; Мизерницкий Ю.Л., Мельникова И.М. Роль комбинированной муколитической терапии при инфекционно-воспалительных заболеваниях органов дыхания у детей. Медицинский совет. 2019; (11): 56–59. DOI:10.21518/2079-701X-2019-11-56-59.; Белевский А.С., Княжеская Н.П. Тиамфеникола глицинат ацетилцистеинат: некоторые аспекты применения при острых и хронических легочных заболеваниях. Практическая пульмонология. 2017; (3): 123–126. Доступно на: https://atmosphere-ph.ru/modules/Magazines/articles/pulmo/pp_3_2017_122.pdf; Tarrant B.J., Le Maitre C., Romero L. et al. Mucoactive agents for chronic, non-cystic fibrosis lung disease: a systematic review and meta-analysis. Respirology. 2017; 22 (6): 1084–1092. DOI:10.1111/resp.13047.; Kellett F., Robert N.M. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir. Med. 2011; 105 (12): 1831–1835. DOI:10.1016/j.rmed.2011.07.019.; Herrero-Cortina B., Alcaraz V., Vilaro J. et al. Impact of hypertonic saline solutions on sputum expectoration and their safety profile in patients with bronchiectasis: a randomized crossover trial. J. Aerosol Med. Pulm. Drug Deliv. 2018; 31 (5): 281–289. DOI:10.1089/jamp.2017.1443.; Daviskas E., Anderson S.D., Gonda I. et al. Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects. Eur. Respir. J. 1996; 9 (4): 725–732. DOI:10.1183/09031936.96.09040725.; Elkins M.R., Robinson M., Rose B.R. et al. A controlled trial of longterm inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med. 2006; 354 (3): 229–240. DOI:10.1056/NEJMoa043900.; Wark P., McDonald V.M. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2018; (9): CD001506. DOI:10.1002/14651858.CD001506.pub4.; Michon A.L., Jumas-Bilak E., Chiron R. et al. Advances toward the elucidation of hypertonic saline effects on Pseudomonas aeruginosa from cystic fibrosis patients. PLoS One. 2014; 9 (2): e90164. DOI:10.1371/journal.pone.0090164.; Garantziotis S., Brezina M., Castelnuovo P., Drago L. The role of hyaluronan in the pathobiology and treatment of respiratory disease. Am. J. Physiol. Lung Cell Mol. Physiol. 2016; 310 (9): L785–795. DOI:10.1152/ajplung.00168.2015.; Qi Q., Ailiyaer Y., Liu R. et al. Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial. Respir. Res. 2019; 20 (1): 73. DOI:10.1186/s12931-019-1042-x.; Hart A., Sugumar K., Milan S.J. et al. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst. Rev. 2014; (5): CD002996. DOI:10.1002/14651858.CD002996.pub3.; Wilkinson M., Sugumar K., Milan S.J. et al. Mucolytics for bronchiectasis. Cochrane Database Syst. Rev. 2014 (5): CD001289. DOI:10.1002/14651858.CD001289.pub2.; Wills P., Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst. Rev. 2002; (1): CD002996. DOI:10.1002/14651858.cd002996.; Redding G.J. Bronchiectasis in children. Pediatr. Clin. North Am. 2009; 56 (1): 157–171. DOI:10.1016/j.pcl.2008.10.014.; Chalmers J.D., Polverino E., Crichton M.L. et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir. Med. 2023; 11 (7): 637–649. DOI:10.1016/S2213-2600(23)00093-0.; Jayaram L., King P.T., Hunt J. et al. Evaluation of high dose N-acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: a randomised placebo-controlled pilot study. Pulm. Pharmacol. Ther. 2023; 84: 102283. DOI:10.1016/j.pupt.2023.102283.; Minov J., Stoleski S., Petrova T. et al. Effects of a long-term use of carbocysteine on frequency and duration of exacerbations in patients with bronchiectasis. Open Access Maced. J. Med. Sci. 2019; 7 (23): 4030–4035. DOI:10.3889/oamjms.2019.697.; Liao Y., Wu Y., Zi K. et al. The effect of N-acetylcysteine in patients with non-cystic fibrosis bronchiectasis (NINCFB): study protocol for a multicentre, double-blind, randomised, placebo-controlled trial. BMC Pulm. Med. 2022; 22 (1): 401. DOI:10.1186/s12890-022-02202-9.; Bradley J.M., Anand R., O’Neill B. et al. A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial. Trials. 2019; 20 (1): 747. DOI:10.1186/s13063-019-3766-9.; Chang A.B., Morgan L.C., Duncan E.L. et al. Reducing exacerbations in children and adults with primary ciliary dyskinesia using erdosteine and/or azithromycin therapy (REPEAT trial): study protocol for a multicentre, double-blind, double-dummy, 2×2 partial factorial, randomised controlled trial. BMJ Open Respir. Res. 2022; 9 (1): e001236. DOI:10.1136/bmjresp-2022-001236.; Serra A., Schito G.C., Nicoletti G., Fadda G. A therapeutic approach in the treatment of infections of the upper airways: thiamphenicol glycinate acetylcysteinate in sequential treatment (systemic-inhalatory route). Int. J. Immunopathol. Pharmacol. 2007; 20 (3): 607–617. DOI:10.1177/039463200702000319.; Blasi F., Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir Med. 2016; 117: 190–197. DOI:10.1016/j.rmed.2016.06.015.; Olofsson A.C., Hermansson M., Elwing H. N-acetyl-L-cysteine affects growth, extracellular polysaccharide production, and bacterial biofilm formation on solid surfaces. Appl. Environ. Microbiol. 2003; 69 (8): 4814–4822. DOI:10.1128/aem.69.8.4814-4822.2003.; Иванчик Н.В., Сухорукова М.В., Чагарян А.Н. и др. In vitro активность тиамфеникола в отношении клинических изолятов Haemophilus influenzae, Streptococcus pneumoniae и Streptococcus pyogenes. Клиническая микробиология и антимикробная химиотерапия. 2021; 23 (1): 92–99. DOI:10.36488/cmac.2021.1.92-99.; Bilton D., Tino G., Barker A.F. et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. 2014; 69 (12): 1073–1079. DOI:10.1136/thoraxjnl-2014-205587.; Lee A.L., Gordon C.S., Osadnik C.R. Exercise training for bronchiectasis. Cochrane Database Syst. Rev. 2021; 4 (4): CD013110. DOI:10.1002/14651858.cd013110.pub2.; Etienne T., Spiliopoulos A., Megevand R. [Bronchiectasis: indication and timing for surgery]. Ann. Chir. 1993; 47 (8): 729–735 (in French).; Yu J.A., Pomerantz M., Bishop A. et al. Lady windermere revisited: treatment with thoracoscopic lobectomy/segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease. Eur. J. Cardiothorac. Surg. 2011; 40 (3): 671–675. DOI:10.1016/j.ejcts.2010.12.028.; Weill D., Benden C., Corris P.A. et al. A consensus document for the selection of lung transplant candidates: 2014 – an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 2015; 34 (1): 1–15. DOI:10.1016/j.healun.2014.06.014.; Fujimoto T., Hillejan L., Stamatis G. Current strategy for surgical management of bronchiectasis. Ann. Thorac Surg. 2001; 72 (5): 1711–1715. DOI:10.1016/s0003-4975(01)03085-5.; Kutlay H., Cangir A.K., Enon S. et al. Surgical treatment in bronchiectasis: analysis of 166 patients. Eur. J. Cardiothorac. Surg. 2002; 21 (4): 634–637. DOI:10.1016/s1010-7940(02)00053-2.; Leard L.E., Holm A.M., Valapour M. et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for heart and lung transplantation. J. Heart Lung Transplant. 2021; 40 (11): 1349–1379. DOI:10.1016/j.healun.2021.07.005.; https://journal.pulmonology.ru/pulm/article/view/4474

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/4474
https://doi.org/10.18093/0869-0189-2024-34-2-158-174

المؤلفون: Xi Li, Guodong Liu, Wei Wu

المصدر: Cancers, Vol 16, Iss 7, p 1406 (2024)

مصطلحات موضوعية: pseudomyxoma peritonei, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, mucin, mucolytic, targeted therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://www.mdpi.com/2072-6694/16/7/1406; https://doaj.org/toc/2072-6694; https://doaj.org/article/6802b239b3b14ca3894a02f7df3ed629

الاتاحة: https://doi.org/10.3390/cancers16071406
https://doaj.org/article/6802b239b3b14ca3894a02f7df3ed629

المؤلفون: Pierachille Santus, Juan Camilo Signorello, Fiammetta Danzo, Giada Lazzaroni, Marina Saad, Dejan Radovanovic

المصدر: Journal of Clinical Medicine, Vol 13, Iss 14, p 4127 (2024)

مصطلحات موضوعية: N-acetyl-L-cysteine, NAC, mucolytic, antioxidant, anti-inflammatory, NKA, Medicine

Relation: https://www.mdpi.com/2077-0383/13/14/4127; https://doaj.org/toc/2077-0383; https://doaj.org/article/22bcece9810042d2bf272e11a04b7c2b

الاتاحة: https://doi.org/10.3390/jcm13144127
https://doaj.org/article/22bcece9810042d2bf272e11a04b7c2b

المؤلفون: Firdaus, Dzikri Anfasa, Jihad, Fikri Hidayatul, Mursaha, Siti Inayah Majreha

المصدر: Halal Studies and Society; Vol 1 No 1 (2024): Januari 2024 ; 37-41 ; Halal Studies and Society; Vol. 1 No. 1 (2024): Januari 2024 ; 3031-416X

مصطلحات موضوعية: Acetaminophen, Cysteine, Halal, Mucolytic, Supplement

Relation: http://journal.ipb.ac.id/index.php/hass/article/view/52976

الاتاحة: http://journal.ipb.ac.id/index.php/hass/article/view/52976
https://doi.org/10.29244/hass.1.1.37-41

المؤلفون: V. N. Antonov, G. L. Ignatova, M. S. Belsner, В. Н. Антонов, Г. Л. Игнатова, М. С. Бельснер

المساهمون: The study was conducted with the support of Zambon Pharma, Исследование проведено при поддержке компании Zambon Pharma

المصدر: PULMONOLOGIYA; Том 34, № 1 (2024); 105-113 ; Пульмонология; Том 34, № 1 (2024); 105-113 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: антиоксидантная активность, mucolytic therapy, antioxidant activity, муколитическая терапия

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/4463/3605; Клячкина И.Л. Все ли мы знаем об ацетилцистеине? Фарматека. 2021; 28 (10): 103–110. DOI:10.18565/pharmateca.2021.10.103-110.; Samuni Y., Goldstein S., Dean O.M., Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim. Biophys. Acta. 2013; 1830 (8): 4117–4129. DOI:10.1016/j.bbagen.2013.04.016.; Izquierdo-Alonso J.L., Pérez-Rial S., Rivera C.G., Peces-Barba G. N-acetylcysteine for prevention and treatment of COVID-19: current state of evidence and future directions. J. Infect. Public Health. 2022; 15 (12): 1477–1483. DOI:10.1016/j.jiph.2022.11.009.; Avdeev S.N., Gaynitdinova V.V., Merzhoeva Z.M., Berikkhanov Z.G. N-acetylcysteine for the treatment of COVID-19 among hospitalized patients. J. Infect. 2022; 84 (1): 94–118. DOI:10.1016/j.jinf.2021.07.003.; Mokra D., Mokry J., Barosova R., Hanusrichterova J. Advances in the use of N-acetylcysteine in chronic respiratory diseases. Antioxidants (Basel). 2023, 12 (9): 1713. DOI:10.3390/antiox12091713.; Cazzola M., Calzetta L., Page C. et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur. Respir. Rev. 2015; 24 (137): 451–461. DOI:10.1183/16000617.00002215.; Grandjean E.M., Berthet P., Ruffmann R., Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther. 2000; 22 (2): 209–221. DOI:10.1016/S0149-2918(00)88479-9.; Stey C., Steurer J., Bachmann S. et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur. Respir. J. 2000; 16 (2): 253–262. DOI:10.1034/j.1399-3003.2000.16b12.x.; Hansen N.C., Skriver A., Brorsen-Riis L. et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir. Med. 1994; 88 (7): 531–535. DOI:10.1016/s0954-6111(05)80337-3.; Huang C., Kuo S., Lin L., Yang Y. The efficacy of N-acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis. Ther. Adv. Respir. Dis. 2023; 17: 17534666231158563. DOI:10.1177/17534666231158563; Tse H.N., Raiteri L., Wong K.Y. et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013; 144 (1): 106–118. DOI:10.1378/chest.12-2357.; Liu X., Hu Z., Zhou H. N-Acetylcysteine improves inflammatory response in COPD patients by regulating Th17/Treg balance through hypoxia inducible factor-1α pathway. Biomed Res. Int. 2021; 2021: 6372128. DOI:10.1155/2021/6372128.; Cazzola M., Calzetta L., Facciolo F. et al. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir. Res. 2017; 18 (1): 26. DOI:10.1186/s12931-016-0500-y.; Flinkman E., Vähätalo I., Tuomisto L.E. et al. Association between blood eosinophils and neutrophils with clinical features in adult-onset asthma. J. Allergy Clin. Immunol. Pract. 2023; 11 (3): 811–821.e5. DOI:10.1016/j.jaip.2022.11.025.; Министерство здравоохранения Российской Федерации. Клинические рекомендации: Внебольничная пневмония у взрослых. 2021. Доступно на: https://cr.minzdrav.gov.ru/recomend/654_1?ysclid=lrvmev1bkv562840552 [Дата обращения: 22.01.24].; Zhang Q., Ju Y., Ma Y., Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: a randomized controlled trial. Medicine (Baltimore). 2018; 97 (45): e13087. DOI:10.1097/MD.0000000000013087.; Kumar V. Pulmonary innate immune response determines the outcome of inflammation during pneumonia and sepsis-associated acute lung injury. Front. Immunol. 2020; 11: 1722. DOI:10.3389/fimmu.2020.01722.; Ornatowski W., Lu Q., Yegambaram M. et al. Complex interplay between autophagy and oxidative stress in the development of pulmonary disease. Redox Biol. 2020; 36: 101679. DOI:10.1016/j.redox.2020.101679.; Chen H., Ma N., Song X. et al. Protective effects of N-acetylcysteine on lipopolysaccharide-induced respiratory inflammation and oxidative stress. Antioxidants (Basel). 2022; 11 (5): 879. DOI:10.3390/antiox11050879; Бронхоэктазы у взрослых больных: клинические рекомендации Европейского респираторного общества. Пульмонология. 2018; 28 (2): 147–168. DOI:10.18093/0869-0189-2018-28-2-147-168.; Subhas E., Rees M. Bronchiectasis. Aust. J. Gen. Pract. 2022; 51 (12): 945–949. DOI:10.31128/AJGP-08-22-6520.; Herrero-Cortina B., Alcaraz V., Vilaró J. et al. Impact of hypertonic saline solutions on sputum expectoration and their safety profile in patients with bronchiectasis: a randomized crossover trial. J. Aerosol Med. Pulm. Drug Deliv. 2018; 31 (5): 281–289. DOI:10.1089/jamp.2017.1443.; Luo A., Liu X., Hu Q. et al. Efficacy of N-acetylcysteine on idiopathic or postinfective non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis protocol. BMJ Open. 2022; 12 (3): e053625. DOI:10.1136/bmjopen-2021-053625.; Qi Q., Ailiyaer Y., Liu R. et al. Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial. Respir. Res. 2019; 20 (1): 73. DOI:10.1186/s12931-019-1042-x.; Кондратьева Е.И., Амелина Е.Л., Чернуха М.Ю. и др. Обзор клинических рекомендаций «Кистозный фиброз (муковисцидоз)» (2020). Пульмонология. 2021; 31 (2): 135–146. DOI:10.18093/0869-0189-2021-31-2-135-146.; Ehre C., Rushton Z. L., Wang B. et al. An improved inhaled mucolytic to treat airway muco-obstructive diseases. Am. J. Respir. Crit. Care Med. 2019; 199 (2): 171–180. DOI:10.1164/rccm.201802-0245oc.; Luppi F., Kalluri M., Faverio P. et al. Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. Respir. Res. 2021; 22 (1): 109. DOI:10.1186/s12931-021-01711-1.; Skov M., Pressler T., Lykkesfeldt J. et al. The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection – a pilot study. J. Cyst. Fibros. 2015; 14 (2): 211–218. DOI:10.1016/j.jcf.2014.09.015.; Zhang R., Song Z., Guan Y. et al. Clinical efficacy and quality of life effect of acetylcysteine plus pirfenidone in patients with pulmonary fibrosis. Am. J. Transl. Res. 2022; 14 (8): 5660–5668. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452344/; Sakamoto S., Kataoka K., Kondoh Y. et al. Diffuse lung diseases research group of the ministry of health, labour and welfare, Japan. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial. Eur. Respir. J. 2021; 57 (1): 2000348. DOI:10.1183/13993003.00348-2020.; Авдеев С.Н., Айсанов З.Р., Белевский А.С. и др. Идиопатический легочный фиброз: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022; 32 (3): 473–495. DOI:10.18093/0869-0189-2022-32-3-473-495.; Arber Raviv S., Alyan M., Egorov E. et al. Lung targeted liposomes for treating ARDS. J. Control. Release. 2022; 346: 421–433. DOI:10.1016/j.jconrel.2022.03.028.; Cazzola M., Rogliani P., Salvi S.S. et al. Use of thiols in the treatment of COVID-19: current evidence. Lung. 2021; 199 (4): 335–343. DOI:10.1007/s00408-021-00465-3.; Di Marco F., Foti G., Corsico A.G. Where are we with the use of N-acetylcysteine as a preventive and adjuvant treatment for COVID-19? Eur. Rev. Med. Pharmacol. Sci. 2022; 26 (2): 715–721. DOI:10.26355/eurrev_202201_27898.; Gamarra-Morales Y., Herrera-Quintana L., Molina-López J. et al. Response to intravenous N-acetylcysteine supplementation in critically Ill patients with COVID-19. Nutrients. 2023; 15 (9): 2235. DOI:10.3390/nu15092235.; Micheletto C., Izquierdo J.L., Avdeev S.N. et al. N-acetylcysteine as a therapeutic approach to post-COVID-19 pulmonary fibrosis adjunctive treatment. Eur. Rev. Med. Pharmacol. Sci. 2022; 26 (13): 4872–4880. DOI:10.26355/eurrev_202207_29212.; Blasi F., Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir. Med. 2016; 117: 190–197. DOI:10.1016/j.rmed.2016.06.015.; Lebeaux D., Ghigo J.M., Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol. Mol. Biol. Rev. 2014; 78 (3): 510–543. DOI:10.1128/MMBR.00013-14.; Aiyer A., Visser S.K., Bye P. et al. Effect of N-acetylcysteine in combination with antibiotics on the biofilms of three cystic fibrosis pathogens of emerging importance. Antibiotics (Basel). 2021; 10 (10): 1176. DOI:10.3390/antibiotics10101176.; https://journal.pulmonology.ru/pulm/article/view/4463

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/4463
https://doi.org/10.18093/0869-0189-2024-34-1-105-113

المؤلفون: Michal Stepan, Premysl Falt, Barbora Pipek, Petr Fojtik, Martin Hanousek, Martin Hill, Ondrej Urban

المصدر: Biomedical Papers, Vol 167, Iss 1, Pp 69-73 (2023)

مصطلحات موضوعية: upper endoscopy, visibility score, mucolytic solution, n-acetylcysteine, simethicon, Medicine

وصف الملف: electronic resource

Relation: https://biomed.papers.upol.cz/artkey/bio-202301-0010_administration-of-mucolytic-solution-before-upper-endoscopy-double-blind-monocentric-randomized-study.php; https://doaj.org/toc/1213-8118; https://doaj.org/toc/1804-7521

URL الوصول: https://doaj.org/article/3c027d46433645e1beb80cafebacff6f

المؤلفون: Vito Terlizzi, Chiara Castellani, Giovanni Taccetti, Beatrice Ferrari

المصدر: Italian Journal of Pediatrics, Vol 48, Iss 1, Pp 1-7 (2022)

مصطلحات موضوعية: Mucolytic agents, LCI, Children, Lung function, Pediatrics, RJ1-570

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1824-7288

URL الوصول: https://doaj.org/article/00997ef1ca204c7d9f57b2afdbbfb777

المؤلفون: K.Yu. Gashynova, K.S. Suska, V.V. Dmytrychenko

المصدر: Infusion & Chemotherapy, Iss 2, Pp 21-28 (2022)

مصطلحات موضوعية: bronchiectasis, nebulizer therapy, inhaled mucolytic, bronchodilators, decametoxinum, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://infusion-chemotherapy.com/index.php/journal/article/view/309; https://doaj.org/toc/2663-0338; https://doaj.org/toc/2709-0957

URL الوصول: https://doaj.org/article/5b6d03c197b8486e9c0e9ce3307af930

المؤلفون: O. I. Simonova, S. G. Bystrova, Yu. V. Gorinova

المصدر: Медицинский совет, Vol 0, Iss 4, Pp 120-127 (2022)

مصطلحات موضوعية: cystic fibrosis, dornase alfa, mucolytic therapy, mucostasis, chronic bronchopulmonary process, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/6776; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/ded6ceba80f54b00b5ba1331de93bbec

المؤلفون: Muralinath E., Pooja Devi, Prasanta Chbukdhara, Sanjib Borah, Kalyan C., Archana Jain, Guruprasad M.

المصدر: Research and Reviews: Journal of Forensic Nursing, 2(1), 1-4, (2023-12-21)

مصطلحات موضوعية: Mucolytic airways, respiratory system, N _ acetyl cysteine. Disulfide bonds, viscosity of mucus, donate alpha, cystic fibrosis, DNA component of mucus, bronchitis. COPD, pneumonia, nausea, bronchoconstrion and covid _ 19

Relation: https://zenodo.org/communities/nurse; https://doi.org/10.5281/zenodo.10416876; https://doi.org/10.5281/zenodo.10416877; oai:zenodo.org:10416877

الاتاحة: https://doi.org/10.5281/zenodo.10416877

المؤلفون: Eoghan Burke, Patricia Harkins, Frank Moriarty, Ibrahim Ahmed

مصطلحات موضوعية: Gastroenterology and hepatology, Oncology and carcinogenesis, Gastric Cancer (GC), oesophagogastroduodenoscopy (OGD), Excess mucus, gastric mucosa, total mucosal visibility scores (TMVS), mucolytic agents, premedication, endoscopy, common malignancy

Relation: 10779/rcsi.24787872.v1; https://figshare.com/articles/journal_contribution/Does_premedication_with_mucolytic_agents_improve_mucosal_visualization_during_oesophagogastroduodenoscopy_a_systematic_review_and_meta-analysis/24787872

الاتاحة: https://figshare.com/articles/journal_contribution/Does_premedication_with_mucolytic_agents_improve_mucosal_visualization_during_oesophagogastroduodenoscopy_a_systematic_review_and_meta-analysis/24787872

المؤلفون: Haena Park, Sunghak Choi, Bong Su Kang, Hyunjong Yu, Jaeil Kim, Ho-Sup Jung, Hoon Eui Jeong, Pahn-Shick Chang

مصطلحات موضوعية: Biochemistry, Medicine, Microbiology, Cell Biology, Pharmacology, Biotechnology, Space Science, Chemical Sciences not elsewhere classified, significantly enhanced capacity, revealing substantial enhancements, physicochemical analysis revealed, oral drug delivery, mucolytic enzyme derived, improved cellular uptake, porcine mucus layer, mucus penetration capability, ht29 coculture models, enhancing mucus permeation, intestinal mucus layer, mucus permeability increased, cell membrane permeation, optimized bromelain payload, lips using caco, lip measured 152, decorated nanoscale liposomes, 2 cell monolayers, fold improvement compared, mucus permeation, permeability compared, liposome membrane

Relation: https://figshare.com/articles/journal_contribution/Bromelain-Decorated_Nanoscale_Liposomes_for_Mucus_Permeation_and_Intestinal_Absorption_in_Oral_Drug_Delivery/24910597

الاتاحة: https://doi.org/10.1021/acsanm.3c04526.s001
https://figshare.com/articles/journal_contribution/Bromelain-Decorated_Nanoscale_Liposomes_for_Mucus_Permeation_and_Intestinal_Absorption_in_Oral_Drug_Delivery/24910597

المؤلفون: Christine Esposito, Martin Kamper, Jessica Trentacoste, Susan Galvin, Halie Pfister, Janice Wang

المصدر: Life ; Volume 13 ; Issue 9 ; Pages: 1835

مصطلحات موضوعية: cystic fibrosis (CF), cystic fibrosis transmembrane conductance regulator (CFTR), highly effective modulator therapy (HEMT), gene-based therapy, antibiotics, bacteriophage, anti-inflammatory, mucolytic therapy

جغرافية الموضوع: agris

وصف الملف: application/pdf

Relation: Medical Research; https://dx.doi.org/10.3390/life13091835

الاتاحة: https://doi.org/10.3390/life13091835